Matching-Adjusted Indirect Comparison of Oral Paclitaxel (Liporaxel®) Versus Weekly Intravenous Paclitaxel in Advanced Gastric Cancer.
5 affiliations
- 1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- 2Healthcare Group, Lee&Ko, Seoul, Korea.
- 3PEMACK, Seoul, Korea.
- 4Daehwa Pharmaceutical, Seoul, Korea.
- 5Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. [email protected].
Abstract
Purpose
Intravenous (IV) paclitaxel is widely used in the treatment of advanced gastric cancer. Liporaxel® is the first orally administered paclitaxel formulation and demonstrated non-inferiority to paclitaxel administered every 3 weeks in the phase III DREAM trial. As no head-to-head trial has compared Liporaxel® with the widely used weekly paclitaxel regimen in gastric cancer, this study aimed to compare their relative efficacy.Materials and methods
This study utilized individual patient data from the DREAM trial and aggregate data for the weekly paclitaxel regimen from a systematic literature review. Given the absence of a common comparator, an unanchored matching-adjusted indirect comparison (MAIC) was performed for progression-free survival (PFS) and overall survival (OS) with weighting based on common and extended variables. Primary and sensitivity analyses were performed according to the effective sample size (ESS).Results
Matching was performed across 5 studies. Despite a reduction in the ESS, baseline patient characteristics remained similarly distributed after matching. In the two studies included in the primary analysis, the adjusted hazard ratios from the unanchored MAIC, based on common variables, were 0.95 (95% confidence interval [CI], 0.72-1.26) and 1.03 (95% CI, 0.81-1.29) for PFS, and 0.94 (95% CI, 0.69-1.28) and 1.06 (95% CI, 0.84-1.34) for OS. The results obtained using the extended variables and sensitivity analyses were consistent with the primary analysis.Conclusions
The efficacy of Liporaxel® and the weekly IV paclitaxel regimen were comparable. This finding supports the previously established non-inferiority evidence and suggests Liporaxel® as a valid treatment option for advanced gastric cancer.
Related
- Tralokinumab Versus Dupilumab for the Treatment of Atopic Dermatitis with Moderate-to-Severe Hand Involvement: A Matching-Adjusted Indirect Comparison
- Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis
- Optimizing the Therapeutic Index: Sequential Intraarterial–Intravenous PRRT with Personalized Volumetric-Adjusted Dosing
- Drug Dosing in Chronic Kidney Disease: Comparison of Standardized eGFR and eGFR Adjusted for Body Surface Area
- Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts
BibTeX
@article{kim2026matchingadjusted,
title = {{Matching-Adjusted Indirect Comparison of Oral Paclitaxel (Liporaxel®) Versus Weekly Intravenous Paclitaxel in Advanced Gastric Cancer.}},
author = {Hyung-Don Kim and Sungju Kim and Eileen J Shin and Jiyeon Lee and Jiwon Lee and Myungchul Lee and Jeongeun Shin and Min-Hee Ryu},
journal = {Journal of gastric cancer},
year = {2026},
month = oct,
doi = {10.5230/jgc.2026.26.e47},
url = {https://europepmc.org/article/MED/42845257},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Matching-Adjusted Indirect Comparison of Oral Paclitaxel (Liporaxel®) Versus Weekly Intravenous Paclitaxel in Advanced Gastric Cancer.
AU - Hyung-Don Kim
AU - Sungju Kim
AU - Eileen J Shin
AU - Jiyeon Lee
AU - Jiwon Lee
AU - Myungchul Lee
AU - Jeongeun Shin
AU - Min-Hee Ryu
PY - 2026
DA - 2026/10/01
JO - Journal of gastric cancer
DO - 10.5230/jgc.2026.26.e47
UR - https://europepmc.org/article/MED/42845257
AB - Purpose Intravenous (IV) paclitaxel is widely used in the treatment of advanced gastric cancer. Liporaxel® is the first orally administered paclitaxel formulation and demonstrated non-inferiority to paclitaxel administered every 3 weeks in the phase III DREAM trial. As no head-to-head trial has compared Liporaxel® with the widely used weekly paclitaxel regimen in gastric cancer, this study aimed to compare their relative efficacy.Materials and methods This study utilized individual patient data from the DREAM trial and aggregate data for the weekly paclitaxel regimen from a systematic literature review. Given the absence of a common comparator, an unanchored matching-adjusted indirect comparison (MAIC) was performed for progression-free survival (PFS) and overall survival (OS) with weighting based on common and extended variables. Primary and sensitivity analyses were performed according to the effective sample size (ESS).Results Matching was performed across 5 studies. Despite a reduction in the ESS, baseline patient characteristics remained similarly distributed after matching. In the two studies included in the primary analysis, the adjusted hazard ratios from the unanchored MAIC, based on common variables, were 0.95 (95% confidence interval [CI], 0.72-1.26) and 1.03 (95% CI, 0.81-1.29) for PFS, and 0.94 (95% CI, 0.69-1.28) and 1.06 (95% CI, 0.84-1.34) for OS. The results obtained using the extended variables and sensitivity analyses were consistent with the primary analysis.Conclusions The efficacy of Liporaxel® and the weekly IV paclitaxel regimen were comparable. This finding supports the previously established non-inferiority evidence and suggests Liporaxel® as a valid treatment option for advanced gastric cancer.
SN - 2093-582X
SN - 2093-5641
ER -